Posted by Michael Wonder on 08 Sep 2022
Revance announces FDA approval of Daxxify (daxibotulinumtoxinA-lanm) for injection, the first and only peptide formulated neuromodulator with long-lasting results
8 September 2022 - Based on the data from SAKURA, Daxxify has the ability to deliver year long results with as few as two treatments per year and has been proven to be effective, generally safe and well tolerated.
Revance Therapeutics today announced that the US FDA has approved Daxxify (daxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.
